



# AHA 20

American Heart Association  
Scientific Sessions  
Nov. 14-16, 2020

[Print this Page for Your Records](#)

[Close Window](#)

**Control/Tracking Number:** 2020-SS-A-16846-AHA

**Activity:** Abstract

**Current Date/Time:** 6/19/2020 1:34:54 PM

## An Online, Accredited Educational Activity Improves The Knowledge Of Physicians In Hyperkalemia Treatment Using Novel Potassium Binding Agents

**Author Block:** Susan H. Gitzinger, Bryan C. Taylor, Joan B. Fowler, Vanessa Carranza, Ashley C. Lilly, Creative Educational Concepts, Lexington, KY

### Abstract:

**Introduction:** Conventional treatment options for hyperkalemia have provided limited benefit with serious adverse events. However, novel potassium binding agents have emerged which are able to significantly lower potassium and an improved tolerability profile. **Hypothesis:** The goal of this educational activity is to improve awareness of emerging agents for the treatment of hyperkalemia to enable clinicians to decrease the burden of hyperkalemia across the continuum of care. **Methods:** Learning and knowledge was objectively assessed by analyzing pre- and post-test results before and after the online educational activity. Statistical testing between pre- and post-tests were conducted via chi square analysis with a priori significance set at 0.05. **Results:** Responses were collected from N=848 participants. Improved learners, as determined by significant ( $P < 0.05$ ) increases in correct responses, were observed in several specific topic areas. However, statistically significant improvement was not observed across all physician specialties. For distinguishing the use of the newer potassium binding agents from sodium polystyrene sulfonate (SPS): Cardiologists - 42% pre-test vs. 56% post-test ( $P < 0.001$ ); Nephrologists - 58% pre-test vs. 69% post-test ( $P = NS$ ); Diabetologists/Endocrinologists - 47% pre-test vs. 65% post-test ( $P = 0.043$ ). For determining key characteristics of newer agents for hyperkalemia (sodium zirconium cyclosilicate and patiomer): Cardiologists - 59% pre-test vs. 87% post-test ( $P < 0.001$ ); Nephrologists - 80% pre-test vs. 84% post-test ( $P = NS$ ); Diabetologists/Endocrinologists - 62% pre-test vs. 85% post-test ( $P = 0.004$ ). When understanding the relationship between hyperkalemia and RAAS inhibition: Cardiologists - 53% pre-test vs. 81% post-test ( $P < 0.001$ ); Nephrologists - 67% pre-test vs. 82% post-test ( $P = 0.026$ ); Diabetologists/Endocrinologists - 53% pre-test vs. 66% post-test ( $P = NS$ ). **Conclusions:** This analysis shows that online, accredited education can significantly improve knowledge of physicians in multiple areas surrounding hyperkalemia and the use of newer potassium binding agents. Results also suggest that ongoing education is needed targeting nephrologists and diabetologists/endocrinologists.

**Category (Complete):** 4.18 Cardiorenal Physiology/Pathophysiology

**Keyword (Complete):** Cardiorenal ; Physician ; Outcomes

**Presentation Preference (Complete):** Poster Only

**Additional Info (Complete):**

**I plan on participating in AHA Scientific Sessions:** As a virtual attendee, joining the event from work/home.

**How did you FIRST become aware of submitting abstracts in 2020 for the American Heart Association Scientific Sessions? (Required):** C. E-mail invitation

**Is this your first time submitting an abstract to Scientific Sessions? (Required):** Yes

**Have you submitted to any of the conferences above? (Required):** No

*If yes, please select all that apply, using the selections below. If no, please select None in Selection 1.*

**Selection 1: (Required)** None

**Selection 2:** None

**Selection 3:** None

**Selection 4:** None

**Selection 5:** None

**Selection 6:** None

**Are you an AHA member? (Required):** No

**Has this research received full or partial funding support from the American Heart Association? (Required):** No

**Disclosure (Required):** There are no unlabeled/unapproved uses of drugs or products.

**Abstract Copyright Transfer Agreement (Required):** Yes

**This abstract is currently on a pre-print server or based on a manuscript that is on a pre-print server. (Required):** No

**Health Tech Featured Science:** Abstract is not applicable

**Payment (Complete):** Your credit card order has been processed on Friday 19 June 2020 at 1:33 PM.

**Status:** Complete

For Programming Related Questions, please [email us!](#)

Need Technical Support?

OASIS Helpdesk at Coe-Truman Technologies, Inc.

Email | [aha@support.ctimeetingtech.com](mailto:aha@support.ctimeetingtech.com)

Phone | 217-398-1792

Helpdesk Hours | Mon-Fri., 7am-6pm CDT

7272 Greenville Avenue

Dallas, Texas 75231

[QASIS Helpdesk](#)

 [Feedback](#)

---

Powered by [cOASIS](#), The Online Abstract Submission and Invitation System <sup>SM</sup>

© 1996 - 2020 [CTI Meeting Technology](#). All rights reserved. [Privacy Policy](#)